Reuters logo
8 months ago
BRIEF-Tonix Pharmaceuticals Holding says intends to commence 12-week phase 3 honor study, evaluating tnx-102 sl, 5.6 mg, in military-related ptsd
January 3, 2017 / 12:27 PM / 8 months ago

BRIEF-Tonix Pharmaceuticals Holding says intends to commence 12-week phase 3 honor study, evaluating tnx-102 sl, 5.6 mg, in military-related ptsd

Jan 3 (Reuters) - Tonix Pharmaceuticals Holding Corp :

* Tonix Pharmaceuticals holding-intends to commence 12-week phase 3 honor study, evaluating tnx-102 sl, 5.6 mg, in military-related ptsd, in Q1 of 2017 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below